TITLE

Diamyd Medical: Diamyd Puts Focus on Pain Projects and Reduces Costs

PUB. DATE
August 2011
SOURCE
Biomedical Market Newsletter;8/23/2011, Vol. 21, p334
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on the shift in the primary development focus of Diamyd Medical AB from diabetes therapy to a portfolio of drug candidates for chronic pain and nervous diseases treatment. It states that the pain portfolio is based on the Nerve Targeting Drug Delivery System's (NTDDS) patented technology. It also mentions that the company has terminated the Phase III program for diabetes therapy Diamyd® to reduces costs and create a strategic leeway for the company.
ACCESSION #
65049060

 

Related Articles

  • Influence Of Low Intensity Laser Therapy On Diabetic Polyneuropathy. Abdel-Raoof, N. A.; Elnhas, N. G.; Elsayed, I. M. // AIP Conference Proceedings;2011, Vol. 1380 Issue 1, p24 

    Diabetic peripheral neuropathy is a consequence of diabetes-mediated impairment of blood flow, and resultant hypoxia of nerves that may develop within 10 years of the onset of diabetes in 40-50% of people with type 1 or type 2 diabetes. Low Intensity Laser Therapy (LILT) has been advocated for...

  • Influence Of Low Intensity Laser Therapy On Diabetic Polyneuropathy. Abdel-Raoof, N. A.; Elnhas, N. G.; Elsayed, I. M. // AIP Conference Proceedings;2011, Vol. 1380 Issue 1, p24 

    Diabetic peripheral neuropathy is a consequence of diabetes-mediated impairment of blood flow, and resultant hypoxia of nerves that may develop within 10 years of the onset of diabetes in 40-50 % of people with type 1 or type 2 diabetes. Low Intensity Laser Therapy (LILT) has been advocated for...

  • Publication of Change in the Total Number of Shares and Votes in Diamyd Medical AB.  // Biomedical Market Newsletter;3/21/2011, p176 

    The article focuses on the total number of votes and shares for the publication of change in Diamyd Medical AB, a Swedish pharmaceutical company. It states that the share capital of the company is 14,789,566.50 Swedish krona (SEK), wherein the total number of votes accounts to 4,252,001 and...

  • Complex Regional Pain Syndrome I. Cleland, Joshua; McRae, Meghann // Journal of Manual & Manipulative Therapy (Journal of Manual & Ma;2002, Vol. 10 Issue 4, p188 

    The purpose of this study was to describe the clinical differential diagnostic process and effective management of an individual presenting with lower-extremity complex regional pain syndrome I (CRPS I). A 50-year-old female 8-weeks status post ORIF right tibia/fibula presented with a warm, red,...

  • National Institutes of Health Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain. Reuben, David B.; Alvanzo, Anika A. H.; Ashikaga, Takamaru; Bogat, G. Anne; Callahan, Christopher M.; Ruffing, Victoria; Steffens, David C. // Annals of Internal Medicine;2/17/2015, Vol. 162 Issue 4, Following p295 

    This National Institutes of Health (NIH) Pathways to Prevention Workshop was cosponsored by the NIH Office of Disease Prevention (ODP), the NIH Pain Consortium, the National Institute on Drug Abuse, and the National Institute of Neurological Disorders and Stroke. A multidisciplinary working...

  • Diamyd Shares Fall On News Of Diabetes Trial Debacle. Sheridan, Corman // BioWorld International;6/20/2007, Vol. 12 Issue 25, p1 

    The article reports on the decision of Stockholm, Sweden-based Diamyd Medical AB to halt the phase II/III clinical trial of Diamyd, a therapeutic vaccine in development for treating autoimmune diabetes. A combination of poor trial design and poor execution has forced the company to invalidate...

  • Diamyd's Shares Tumble on Phase II Gene Therapy Miss. Sheridan, Cormac // BioWorld International;7/5/2012, Vol. 17 Issue 27, p1 

    The article reports on the decline in shares in Diamyd Medical AB following news that its gene therapy treatment for cancer pain missed the primary endpoint in a Phase II placebo-controlled trial. The study found no difference in average pain scores among patients receiving a single dose of the...

  • Diamyd Climbs on $625M Type I Diabetes Deal.  // Bioworld Week;6/28/2010, Vol. 18 Issue 26, p4 

    The article reports on the deal to develop the Type I diabetes, entered by Diamyd Medical AB in Sweden.

  • Information about Summons to the Annual General Meeting of Diamyd Medical AB.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p138 

    The article offers information on the Annual General Meeting of Diamyd Medical AB, to be held on December 7, 2011.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics